Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer

KODAZ H., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ ELPEN Ç., HACIBEKİROĞLU İ., ...Daha Fazla

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.1, sa.1, ss.1-7, 2017 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 1 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.14744/ejmo.2017.22931
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Other Indexes
  • Sayfa Sayıları: ss.1-7
  • Anahtar Kelimeler: KRAS, NRAS, HRAS, cancer, K-RAS, BRAF MUTATIONS, H-RAS, POINT MUTATIONS, ONCOGENIC MUTATIONS, CELL CARCINOMA, N-RAS, GENOMIC CHARACTERIZATION, GENE-MUTATIONS, ACTIVATION
  • Marmara Üniversitesi Adresli: Hayır

Özet

RAS oncogene affects numerous cellular functions including growth, proliferation, apoptosis, migration, division and differentiation of the cells. It has 3 known isoforms as Harvey- RAS (HRAS), Kirsten - RAS (KRAS) and Neuroblastoma-RAS (NRAS). RAS has an intrinsic GTPase activity. It encodes proteins binding the guanine nucleotides. KRAS and HRAS were discovered in studies carried out on viruses leading to cancer. Retroviral oncogenes related to murine sarcoma virus genes (Kristen Rat Sarcoma Virus and Murine Sarcoma Virus) were discovered in 1982. These two oncogenes are similar to human KRAS. Approximately 30% of all human cancers have ras genes. Mutations in KRAS account for about 85% for all RAS mutations in human tumors, NRAS is about 11-15%, and HRAS is about 1%.